Stock listing
BOATS:SERA Sera Prognostics, Inc. Stock
US listing (BOATS) of Sera Prognostics, Inc. · home listing NASDAQ:SERA
Follow Sera Prognostics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:SERA
$1.81 USD -0.10 (-5.2%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:SERA
- Day range
- $1.80 – $1.87 USDNov 20, 2026
- Volume
- 94,600 sharesNov 20, 2026
- Market cap
- $69.65M USDAt the close on Nov 20, 2026 · price × 38.48M shares outstanding
- 52-week range
- $1.56 – $3.85 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $55,934 USDMedian day 16,867 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:SERA · Home | $1.81 USD | -0.10 (-5.2%) | 94,600 | $1.821 | $1.87 | $1.80 | $1.91 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SERA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.81 | -0.10 | -5.2% | $1.821 | $1.87 | $1.80 | 94,600 | |
| $1.91 | -0.09 | -4.5% | $2.00 | $2.00 | $1.895 | 10,451 | |
| $2.00 | +0.06 | +3.1% | $1.92 | $2.005 | $1.91 | 35,253 | |
| $1.94 | -0.07 | -3.5% | $2.13 | $2.14 | $1.92 | 25,532 | |
| $2.01 | +0.03 | +1.5% | $1.96 | $2.04 | $1.95 | 28,138 | |
| $1.98 | +0.04 | +2.1% | $1.97 | $2.055 | $1.92 | 18,791 | |
| $1.94 | -0.05 | -2.5% | $2.05 | $2.05 | $1.91 | 84,541 | |
| $1.99 | -0.20 | -9.1% | $2.175 | $2.175 | $1.965 | 53,388 | |
| $2.19 | 0.00 | 0.0% | $2.01 | $2.218 | $2.01 | 30,378 | |
| $2.19 | +0.11 | +5.3% | $2.08 | $2.22 | $2.00 | 218,745 | |
| $2.08 | +0.065 | +3.2% | $2.00 | $2.08 | $2.00 | 21,631 | |
| $2.015 | +0.085 | +4.4% | $1.96 | $2.058 | $1.96 | 93,572 | |
| $1.93 | -0.06 | -3.0% | $1.96 | $2.05 | $1.93 | 14,951 | |
| $1.99 | -0.05 | -2.5% | $2.05 | $2.07 | $1.96 | 22,566 | |
| $2.04 | -0.02 | -1.0% | $2.09 | $2.09 | $2.03 | 85,986 | |
| $2.06 | +0.03 | +1.5% | $2.095 | $2.095 | $2.03 | 16,867 | |
| $2.03 | -0.02 | -1.0% | $2.03 | $2.03 | $2.03 | 516 | |
| $2.05 | +0.01 | +0.5% | $2.04 | $2.07 | $2.03 | 13,568 | |
| $2.04 | +0.01 | +0.5% | $2.039 | $2.08 | $2.03 | 25,414 | |
| $2.03 | -0.01 | -0.5% | $2.04 | $2.10 | $2.03 | 25,000 | |
| $2.04 | +0.01 | +0.5% | $2.03 | $2.04 | $2.03 | 31,200 | |
| $2.03 | 0.00 | 0.0% | $2.03 | $2.045 | $2.03 | 24,200 | |
| $2.03 | 0.00 | 0.0% | $2.06 | $2.06 | $2.025 | 31,300 | |
| $2.03 | -0.03 | -1.5% | $2.04 | $2.065 | $2.03 | 5,300 | |
| $2.06 | +0.03 | +1.5% | $2.03 | $2.061 | $2.03 | 3,500 | |
| $2.03 | -0.04 | -1.9% | $2.07 | $2.09 | $2.03 | 13,300 | |
| $2.07 | +0.03 | +1.5% | $2.03 | $2.07 | $2.03 | 5,800 | |
| $2.04 | -0.03 | -1.4% | $2.04 | $2.047 | $2.03 | 4,700 | |
| $2.07 | +0.03 | +1.5% | $2.06 | $2.099 | $2.03 | 13,800 | |
| $2.04 | +0.02 | +1.0% | $2.01 | $2.10 | $2.01 | 6,300 | |
| $2.02 | -0.05 | -2.4% | $2.21 | $2.21 | $2.01 | 13,400 | |
| $2.07 | +0.02 | +1.0% | $2.01 | $2.07 | $2.01 | 800 | |
| $2.05 | +0.05 | +2.5% | $2.12 | $2.12 | $2.02 | 4,400 | |
| $2.00 | -0.09 | -4.3% | $2.08 | $2.15 | $2.00 | 22,900 | |
| $2.09 | +0.05 | +2.5% | $2.04 | $2.15 | $2.04 | 21,900 | |
| $2.04 | -0.05 | -2.4% | $2.05 | $2.06 | $2.02 | 6,700 | |
| $2.09 | +0.08 | +4.0% | $2.01 | $2.12 | $2.01 | 11,500 | |
| $2.01 | -0.01 | -0.5% | $2.075 | $2.075 | $2.01 | 4,300 | |
| $2.02 | -0.02 | -1.0% | $2.02 | $2.043 | $2.01 | 6,900 | |
| $2.04 | -0.07 | -3.3% | $2.085 | $2.085 | $2.00 | 12,800 | |
| $2.11 | +0.05 | +2.4% | $2.14 | $2.14 | $2.07 | 5,400 | |
| $2.06 | -0.07 | -3.3% | $2.13 | $2.20 | $2.06 | 13,900 | |
| $2.13 | +0.01 | +0.5% | $2.13 | $2.175 | $2.12 | 10,410 | |
| $2.12 | +0.035 | +1.7% | $2.12 | $2.20 | $2.12 | 17,003 | |
| $2.085 | +0.015 | +0.7% | $2.07 | $2.16 | $2.07 | 92,100 | |
| $2.07 | +0.05 | +2.5% | $2.08 | $2.08 | $2.04 | 7,200 | |
| $2.02 | +0.03 | +1.5% | $2.04 | $2.04 | $2.00 | 10,900 | |
| $1.99 | -0.01 | -0.5% | $1.97 | $2.02 | $1.96 | 25,500 | |
| $2.00 | -0.03 | -1.5% | $2.035 | $2.06 | $1.987 | 31,800 | |
| $2.03 | -0.02 | -1.0% | $2.05 | $2.055 | $1.997 | 26,400 | |
| $2.05 | +0.05 | +2.5% | $2.00 | $2.06 | $1.995 | 72,100 | |
| $2.00 | -0.01 | -0.5% | $2.01 | $2.06 | $2.00 | 8,300 | |
| $2.01 | -0.01 | -0.5% | $2.00 | $2.04 | $1.98 | 64,100 | |
| $2.02 | +0.04 | +2.0% | $2.00 | $2.05 | $1.97 | 10,500 | |
| $1.98 | -0.03 | -1.5% | $2.03 | $2.06 | $1.98 | 15,300 | |
| $2.01 | -0.07 | -3.4% | $2.01 | $2.18 | $1.97 | 15,400 | |
| $2.08 | -0.04 | -1.9% | $2.09 | $2.16 | $2.08 | 14,700 | |
| $2.12 | +0.05 | +2.4% | $2.08 | $2.177 | $2.08 | 9,500 | |
| $2.07 | +0.04 | +2.0% | $2.07 | $2.09 | $2.05 | 23,100 | |
| $2.03 | -0.06 | -2.9% | $2.11 | $2.20 | $1.98 | 51,400 | |
| $2.09 | -0.09 | -4.1% | $2.18 | $2.18 | $2.09 | 7,300 | |
| $2.18 | 0.00 | 0.0% | $2.12 | $2.21 | $2.12 | 17,800 | |
| $2.18 | +0.04 | +1.9% | $2.14 | $2.211 | $2.06 | 19,400 | |
| $2.14 | +0.04 | +1.9% | $2.09 | $2.16 | $2.085 | 14,500 | |
| $2.10 | +0.11 | +5.5% | $1.99 | $2.10 | $1.99 | 30,900 |
- Ticker
- BOATS:SERA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Nov 4, 2026
SERA Prognostics reports third quarter 2026 financial results
Latest earnings call · Nov 4, 2026
Sera Prognostics (NASDAQ:SERA) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 4, 2026
Q3 2026 Earnings Presentation
Earnings · 15 slides
Latest news
SERA Prognostics reports third quarter 2026 financial results
Nov 4, 2026
Closed $2.08 (+3.2%) on Nov 5, 2026
SERA Prognostics announces conference call and webcast of third quarter fiscal year 2026 financial results on November 4, 2026
Oct 21, 2026
Closed $2.04 (+0.5%) on Oct 22, 2026
SERA Prognostics appoints Scott Gleason Chief Financial Officer
Aug 19, 2026
Closed $2.10 (+5.5%) on Aug 20, 2026
SERA Prognostics reports second quarter 2026 financial results
Aug 12, 2026
Closed $2.01 (-0.5%) on Aug 13, 2026
SERA Prognostics announces conference call and webcast of second quarter fiscal year 2026 financial results on August 12, 2026
Jul 29, 2026
Closed $2.10 (+2.4%) on Jul 30, 2026
PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE
Jul 9, 2026
Closed $1.97 (-4.4%) on Jul 10, 2026
SERA Prognostics announces appointment of Mark Capone to its board of directors
Jun 30, 2026
Closed $2.03 (+11.5%) on Jul 1, 2026
SERA Prognostics collaborates on ARPA-H award to advance point-of-care diagnostic for safer birth
Jun 24, 2026
Closed $1.80 (-2.2%) on Jun 24, 2026
SERA applauds Illinois initiative to expand Medicaid coverage for proteomic blood testing in pregnancy
Jun 23, 2026
Closed $1.80 (-2.2%) on Jun 24, 2026
SERA Prognostics announces board transition
Jun 1, 2026
Closed $2.04 (-6.8%) on Jun 2, 2026
Sera Prognostics, Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 17 in the last 12 months · 92 in all · newest Nov 4, 2026 · oldest 2021
- Calls
- 21 calls with a replay · 21 with a transcript · latest Nov 4, 2026
- Decks
- 10 decks · latest Nov 4, 2026
Where Sera Prognostics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:SERA · Home listing | NASDAQ | United States | USD |
| BOATS:SERA · This page | BOATS | United States | USD |
Valuation
EV/sales 300× against a median of 4.9×: the highest of 11 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $28.84M USD
- P/E
- Loss
- EV/sales
- 300×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.3×
- Gross margin
- −103.1%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 0.57
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Sera Prognostics, Inc. · NASDAQ:SERA | US$69.65M | US$28.84M | n/a | 300× | n/a | 1.3× | n/a | 0.1× | 0.57 |
| Nightingale Health Oyj Class B · OMXHEX:HEALTH | US$77.17M | US$36.79M | n/a | 6.1× | n/a | 1.4× | −335.7% | 0.0× | n/a |
| Lucid Diagnostics Inc. · NASDAQ:LUCD | US$77.14M | US$77.63M | n/a | 14.3× | n/a | 13.0× | −892.8% | 3.1× | 1.36 |
| Seer, Inc. · NASDAQ:SEER | US$75.91M | −US$58.25M | n/a | −4.1× | n/a | 0.4× | −450.9% | 0.1× | 1.03 |
| Selvita SA · GPW:SLV | US$75.22M | US$113.4M | n/a | 1.4× | 9.1× | 1.0× | −0.6% | 0.5× | n/a |
| BioPorto A/S · OMXCOP:BIOPOR | US$68.30M | US$58.06M | 53.8× | 10.7× | n/a | 5.7× | 23.3% | 0.1× | n/a |
| Nanoform Finland Oyj · OMXHEX:NANOFH | US$66.63M | US$52.80M | n/a | 11.9× | n/a | 1.7× | −339.1% | 0.2× | n/a |
| Applied BioCode Corp. · TWSE:6598 | US$64.88M | US$49.53M | n/a | 2.5× | n/a | 3.0× | −7.3% | 0.1× | n/a |
| Insight Molecular Diagnostics Inc. · NASDAQ:IMDX | US$64.53M | US$55.70M | n/a | 28.3× | n/a | n/a | n/a | n/a | 1.77 |
| Gentian Diagnostics ASA · OSL:GENT | US$62.79M | US$53.42M | n/a | 2.7× | 38.0× | 3.2× | −2.6% | 0.0× | n/a |
| Prestige Biologics Co., Ltd. · KRX:334970 | US$61.06M | US$72.08M | n/a | 3.6× | n/a | 0.9× | −192.1% | 0.2× | n/a |
| Median of the others | US$67.46M | US$54.56M | 53.8× | 4.9× | 23.5× | 1.7× | −192.1% | 0.1× | 1.36 |
Forecasts
4 strong buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 5.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.66 · 3 analysts
- Revenue, year to Dec 2026
- 200K · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Zhenya Lindgardt | President and CEO |
| Scott Gleason | Chief Financial Officer |
| Benjamin G. Jackson | General Counsel |
| Jennifer Zibuda | Head of Investor Relations |
| Angie Fox | VP of Clinical Operations |
| Nikki Martin | VP of Quality and Regulatory |
| Tiffany Inglis | Chief Medical Officer & VP Medical Affairs |
| Adrienne Lugo | Head of Sales & Strategic Accounts |
| Cassondra Mize | Head of Marketing |
| Jay Boniface | Chief Scientific Officer |
| Lee Anderson | Chief Commercial Officer |
| Liana Burns | Head of Payer, Government & Strategic Partnerships |
Board
| Director | Role |
|---|---|
| Mark Capone | Director |
Events
- Next results
- Mar 17, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Sera Prognostics (NASDAQ:SERA) Q3 2026 Earnings Call | Wed, Nov 04, 2026 · 5:00 PM ET | Replay |
| Sera Prognostics (NASDAQ:SERA) Q2 2026 Earnings Call | Wed, Aug 12, 2026 · 5:00 PM ET | Replay |
| Sera Prognostics (NASDAQ:SERA) Q1 2026 Earnings Call | Wed, May 06, 2026 · 5:00 PM ET | Replay |
| Sera Prognostics (NASDAQ:SERA) Q4 2025 Earnings Call | Wed, Mar 18, 2026 · 5:00 PM ET | Replay |
| Sera Prognostics (NASDAQ:SERA) Q3 2025 Earnings Call | Thu, Nov 13, 2025 · 5:00 PM ET | Replay |
| Sera Prognostics (NASDAQ:SERA) Q2 2025 Earnings Call | Wed, Aug 06, 2025 · 5:00 PM ET | Replay |
| Sera Prognostics (NASDAQ:SERA) Q1 2025 Earnings Call | Wed, May 07, 2025 · 5:00 PM ET | Replay |
| Sera Prognostics (NASDAQ:SERA) Q4 2024 Earnings Call | Wed, Mar 19, 2025 · 5:00 PM ET | Replay |
| Sera Prognostics (NASDAQ:SERA) Q3 2024 Earnings Call | Wed, Nov 06, 2024 · 5:00 PM ET | Replay |
| Sera Prognostics (NASDAQ:SERA) Q2 2024 Earnings Call | Wed, Aug 07, 2024 · 5:00 PM ET | Replay |
All 21 calls
| Call | When | Status |
|---|---|---|
| Sera Prognostics (NASDAQ:SERA) Q1 2024 Earnings Call | Wed, May 08, 2024 · 5:00 PM ET | Replay |
| Sera Prognostics (NASDAQ:SERA) Q4 2023 Earnings Call | Wed, Mar 20, 2024 · 5:00 PM ET | Replay |
| Sera Prognostics (NASDAQ:SERA) Q3 2023 Earnings Call | Wed, Nov 08, 2023 · 5:00 PM ET | Replay |
| Sera Prognostics (NASDAQ:SERA) Q2 2023 Earnings Call | Wed, Aug 09, 2023 · 5:00 PM ET | Replay |
| Sera Prognostics (NASDAQ:SERA) Q1 2023 Earnings Call | Wed, May 10, 2023 · 5:00 PM ET | Replay |
| Sera Prognostics (NASDAQ:SERA) Q4 2022 Earnings Call | Wed, Mar 22, 2023 · 5:00 PM ET | Replay |
| Sera Prognostics (NASDAQ:SERA) Q3 2022 Earnings Call | Wed, Nov 09, 2022 · 5:00 PM ET | Replay |
| Sera Prognostics (NASDAQ:SERA) Q2 2022 Earnings Call | Wed, Aug 10, 2022 · 5:00 PM ET | Replay |
| Sera Prognostics (NASDAQ:SERA) Q1 2022 Earnings Call | Tue, May 10, 2022 · 5:00 PM ET | Replay |
| Sera Prognostics (NASDAQ:SERA) Q4 2021 Earnings Call | Tue, Mar 29, 2022 · 5:00 PM ET | Replay |
| Sera Prognostics (NASDAQ:SERA) Q3 2021 Earnings Call | Tue, Nov 09, 2021 · 5:00 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | +3.2% |
| Q2 2026 | Aug 12, 2026 · After close | −0.5% |
| Q1 2026 | May 6, 2026 · After close | +6.1% |
| Q4 2025 | Mar 25, 2026 | −2.0% |
| Q3 2025 | Nov 13, 2025 · After close | +0.3% |
| Q2 2025 | Aug 6, 2025 · After close | −5.5% |
| Q1 2025 | May 7, 2025 · After close | −11.7% |
| Q4 2024 | Mar 19, 2025 | −3.7% |
| Q3 2024 | Nov 6, 2024 · After close | −12.7% |
| Q2 2024 | Aug 7, 2024 · After close | +0.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | +5.3% |
| Q4 2023 | Mar 20, 2024 · After close | +3.8% |
| Q3 2023 | Nov 8, 2023 · After close | −7.6% |
| Q2 2023 | Aug 9, 2023 · After close | +3.2% |
| Q1 2023 | May 10, 2023 · After close | +0.6% |
| Q4 2022 | Mar 22, 2023 · After close | −6.8% |
| Q3 2022 | Nov 9, 2022 · After close | +10.8% |
| Q2 2022 | Aug 10, 2022 · After close | +2.8% |
| Q1 2022 | May 10, 2022 · After close | −7.1% |
| Q4 2021 | Mar 29, 2022 · After close | −7.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 15 slides | Nov 4, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 38 slides | Aug 12, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 38 slides | Mar 18, 2026 |
| Investor Presentation (January 2026) | Investor deck | 38 slides | Jan 8, 2026 |
| Investor Presentation (September 2025) | Investor deck | 31 slides | Sep 5, 2025 |
| Technical Presentation (March 2025) | Technical | 25 slides | Mar 19, 2025 |
| Corporate Update (January 2025) | Corporate update | 39 slides | Jan 31, 2025 |
| Investor Presentation (January 2025) | Investor deck | 34 slides | Jan 13, 2025 |
| Investor Presentation (March 2024) | Investor deck | 31 slides | Mar 20, 2024 |
| Corporate Update (September 2023) | Corporate update | 40 slides | Sep 25, 2023 |
Financings
| Raise | Date |
|---|---|
| Public offering of class A common stock and pre-funded warrants Announced: about US$50M · US$4 a share · Jefferies +3 Dealers: Jefferies (co-lead), TD Cowen (co-lead), William Blair (co-lead), RBC Capital Markets Use of proceeds: Expand US commercial infrastructure, prepare EU expansion, fund PreTRM adoption studies including a potential FDA submission, and general corporate purposes | Feb 10, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Jul 14, 2021.
- Price
- US$16.00 a share
- Shares offered
- 4,687,500 shares of Class A common stock
- Offering size
- US$75 million
- Underwriters' option
- Up to 703,125 more shares
- Listing
- SERA on the Nasdaq Global Market
- Underwriters
- Citigroup, Cowen, William Blair · In the order on the cover
- Shares delivered
- On or about Jul 19, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 29, 2021 |
| Filed publicly | Jun 11, 2021 |
| Amended once | Jul 8, 2021 |
| Shares registered with an exchange | Jul 14, 2021 |
| Declared effective by the SEC | Jul 14, 2021 |
| Final prospectus, with the price | Jul 16, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 16, 2021 |
| EFFECT · Notice that a registration is effective | Jul 14, 2021 |
| CERT · Exchange's certificate of listing | Jul 14, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 14, 2021 |
| CORRESP · Letter to the SEC | Jul 12, 2021 |
| CORRESP · Letter to the SEC | Jul 12, 2021 |
| S-1/A · Registration statement, amended | Jul 8, 2021 |
| CORRESP · Letter to the SEC | Jun 21, 2021 |
| CORRESP · Letter to the SEC | Jun 11, 2021 |
| S-1 · Registration statement | Jun 11, 2021 |
All 18 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Jun 7, 2021 |
| DRSLTR · Letter to the SEC with a draft | May 27, 2021 |
| DRS/A · Draft registration statement, amended | May 27, 2021 |
| UPLOAD · Letter from the SEC | May 14, 2021 |
| DRSLTR · Letter to the SEC with a draft | May 5, 2021 |
| DRS/A · Draft registration statement, amended | May 5, 2021 |
| UPLOAD · Letter from the SEC | Apr 26, 2021 |
| DRS · Draft registration statement | Mar 29, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 16, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 81.0K | 77.0K | 306.0K | 268.0K | 82.0K | 25.0K | 36.0K |
| Cost of revenue | 164.0K | 82.0K | 210.0K | 193.0K | 37.0K | 11.0K | 18.0K |
| Gross profit | -83.0K | -5.00K | 96.0K | 75.0K | 45.0K | 14.0K | 18.0K |
| Research and development | 13.2M | 14.7M | 15.2M | 14.2M | 11.0M | 7.78M | 9.35M |
| Selling, general and administrative | 16.7M | 16.1M | 16.3M | 16.8M | 14.1M | 6.56M | 4.28M |
| Operating income | -36.5M | -36.6M | -39.8M | -45.7M | -35.4M | -18.0M | -16.6M |
| Depreciation and amortization | 940.0K | 833.0K | 900.0K | 756.0K | 659.0K | 895.0K | 946.0K |
| EBITDA | -35.6M | -35.8M | -38.9M | -44.9M | -34.7M | -17.1M | -15.6M |
| Interest expense | 9.00K | 28.0K | 55.0K | 61.0K | 746.0K | 1.84M | 1.97M |
| Income before tax | -31.9M | -32.9M | -36.2M | -44.2M | -35.0M | -19.8M | -16.5M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 3.92M |
| Net income | -31.9M | -32.9M | -36.2M | -44.2M | -35.0M | -19.8M | -16.5M |
| Earnings per share, basic | -0.67 | -0.99 | -1.16 | -1.43 | -2.33 | -12.76 | -0.91 |
| Earnings per share, diluted | -0.67 | -0.99 | -1.16 | -1.43 | -2.33 | -12.76 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.94M | 4.04M | 3.88M | 29.9M | 58.9M | 13.5M | 21.4M |
| Short-term investments | 35.3M | 42.2M | 45.2M | 52.8M | 46.2M | 0 | |
| Receivables | 12.0K | 34.0K | 160.0K | 113.0K | 27.0K | 2.00K | 1.00K |
| Inventory | 1 | 1 | |||||
| Current assets | 40.8M | 47.6M | 61.3M | 90.1M | 110.3M | 13.7M | 21.6M |
| Property, plant and equipment | 1.77M | 965.0K | 1.64M | ||||
| Total assets | 101.9M | 72.6M | 95.4M | 116.3M | 147.0M | 14.8M | 23.3M |
| Accounts payable | 862.0K | 1.97M | 1.05M | 1.55M | 1.20M | 441.0K | 748.0K |
| Current liabilities | 24.2M | 24.8M | 24.4M | 15.5M | 8.41M | 11.2M | 5.90M |
| Long-term debt | 348.0K | 5.44M | |||||
| Total debt | 2.34M | 840.0K | 1.86M | 2.83M | 128.0K | 8.57M | 9.31M |
| Total liabilities | 26.5M | 24.8M | 25.3M | 17.4M | 8.46M | 12.3M | 12.3M |
| Shareholders' equity | 75.4M | 47.8M | 70.2M | 98.9M | 138.6M | -125.6M | 11.0M |
| Shares outstanding | 47.7M | 33.2M | 31.2M | 30.9M | 30.8M | 18.1M | 18.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -25.6M | -14.2M | -27.2M | -34.6M | -31.6M | -16.9M | -19.3M |
| Capital spending | -726.0K | -56.0K | -128.0K | -791.0K | -1.30M | -149.0K | -109.0K |
| Free cash flow | -26.3M | -14.2M | -27.3M | -35.4M | -32.9M | -17.0M | -19.4M |
| Cash from investing | -28.5M | 11.7M | 438.0K | 5.55M | -82.6M | -149.0K | -6.00K |
| Cash from financing | 54.0M | 2.61M | 752.0K | 5.00K | 159.6M | 9.16M | 33.0M |
| Share buybacks | 308.0K | 167.3M | |||||
| Change in cash | -99.0K | 163.0K | -26.0M | -29.1M | 45.4M | -7.86M | 13.7M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 13, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 1, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 19, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 1, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 30, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 8, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 4, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Jun 1, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jun 1, 2026 | Management or board change | SEC |
| 144 · Notice of proposed sale | May 12, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 1, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 24, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 24, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Mar 18, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 18, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 18, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 18, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 12, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 24, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 27, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 8, 2026 | Current report | SEC |
| 8-K · Current report | Jan 7, 2026 | Current report | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 30, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 11, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 11, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 11, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 11, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 11, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 11, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 10, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 8, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 26, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 24, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 6, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 6, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 4, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 15, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 7, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 6, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 6, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 12, 2025 | Other filings | SEC |
| 4/A · Change in ownership, amended | Sep 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 9, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 9, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 9, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 9, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 8, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 5, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 5, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 2, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 29, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 20, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 20, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
This page holds 200 of 660 filings. Open Filings
Cap table
Built by 6ix from Sera Prognostics, Inc.’s releases · as of Feb 10, 2025
- Common shares
- 38,481,707
- Fully diluted
- 38,481,707
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 38,481,707 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 38,481,707 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jay M. Moyes Other companies: BioCardia, Inc. (Board Member · Since at least Oct 24, 2016); SiNtx Technologies, Inc. (Audit Committee Chair · Since at least Feb 12, 2014); Puma Biotechnology Inc (Director · Since at least Apr 27, 2012); Achieve Life Sciences, Inc. (Director · Aug 1, 2017 – May 31, 2022 · Past); Osiris Therapeutics Inc (Director · Aug 3, 2006 – Feb 12, 2013 · Past); Myriad Genetics, Inc. (Chief Financial Officer · Feb 10, 2006 – Oct 15, 2007 · Past) | Chief Financial Officer · Jul 14, 2021 – Jun 7, 2023 · Past |
| Jeffrey Elliott Other companies: ICON plc (Director · Since at least Jun 1, 2026); Quanterix Corporation (COO of Exact Sciences · Since at least Aug 19, 2024); Exagen Inc. (Director · Sep 18, 2019 – Jun 18, 2020 · Past); EXACT Sciences Corporation (Chief Financial Officer · Nov 8, 2016 – Apr 30, 2024 · Past) | Director · Since at least Mar 20, 2025 |
| Kim Kamdar Other companies: Evofem Biosciences, Inc. (Member of the Board of Directors · Since at least Nov 19, 2014); Singular Genomics Systems Inc (Director · May 26, 2021 – Feb 21, 2025 · Past); Vyome Holdings, Inc. (Director · Oct 5, 2016 – Sep 16, 2020 · Past); Syndax Pharmaceuticals, Inc. (Director · Mar 2, 2016 – Oct 31, 2016 · Past) | Director · Since at least Jul 14, 2021 |
| Sandra A.J. Lawrence Other companies: Brixmor Property Group Inc. (Director · Since at least Dec 24, 2021); Evergy, Inc. (Director · Since at least Jun 4, 2018); American Shared Hospital Services (Director · Sep 7, 2017 – Jun 25, 2021 · Past); Westar Energy Inc (Director · Jan 3, 2006 – Jun 4, 2018 · Past) | Director · Since at least Nov 29, 2021 |
| Douglas Carl Fisher Other companies: CERo Therapeutics Holdings, Inc. (President · Oct 5, 2021 – Feb 14, 2024 · Past); Precipio, Inc. (Director · Sep 26, 2017 – Oct 27, 2023 · Past); Vyome Holdings, Inc. (Director · Oct 5, 2016 – Sep 16, 2020 · Past) | Chief Business Officer · Jul 14, 2021 – Jan 10, 2022 · Past |
| Jane F Barlow Other companies: Viracta Therapeutics Inc (Director · Aug 14, 2021 – Jun 20, 2024 · Past); Momenta Pharmaceuticals Inc (Director · Dec 11, 2019 – Oct 1, 2020 · Past); TherapeuticsMD, Inc. (Director · Mar 27, 2018 – Aug 12, 2019 · Past) | Director · Since at least Apr 11, 2022 |
| Mark Capone Other companies: Mesa Laboratories, Inc. (Director · Since at least Jan 8, 2024); Constellation Alpha Capital Corp (Director · Jul 18, 2022 – Jun 1, 2023 · Past); Myriad Genetics, Inc. (President & C.E.O. · Aug 19, 2016 – Sep 30, 2019 · Past) | Director · Since at least Jun 30, 2026 |
| Mansoor Raza Mirza Other companies: Acrivon Therapeutics, Inc. (Chief Medical Officer · Since at least Apr 9, 2025); Karyopharm Therapeutics Inc. (Director · Since at least Nov 5, 2013) | Director · Since at least Jul 14, 2021 |
| Benjamin G. Jackson Other companies: Myriad Genetics, Inc. (Former E.V.P., General Counsel · Jul 1, 2019 – Apr 12, 2021 · Past) | General Counsel · Since at least Jul 14, 2021 |
| Gregory C Critchfield Other companies: Myriad Genetics, Inc. (President Myriad Genetic Labs · Feb 16, 2006 – Sep 15, 2009 · Past) | Director · Since at least Jul 14, 2021 |
All 35 people
| Person | Seat |
|---|---|
| Robert Gardner Harrison Other companies: Myriad Genetics, Inc. (Chief Information Officer · Jan 1, 2008 – Sep 17, 2014 · Past) | Chief Information Officer · Since at least Nov 1, 2021 |
| Scott Gleason Other companies: OraSure Technologies, Inc. (Interim CFO/SVP IR · Sep 17, 2021 – May 21, 2022 · Past) | Chief Financial Officer · Since at least Aug 19, 2026 |
| Adrienne Lugo | Head of Sales & Strategic Accounts · Since at least Nov 5, 2026 |
| Angie Fox | VP of Clinical Operations · Since at least Nov 5, 2026 |
| Austin Aerts | Chief Financial Officer · Since at least Jun 7, 2023 |
| Cassondra Mize | Head of Marketing · Since at least Nov 5, 2026 |
| Dyaarl Lee Anderson Jr | Chief Commercial Officer · Since at least May 19, 2025 |
| Jay Boniface | Chief Scientific Officer · Since at least Nov 5, 2026 |
| Jeff Elliott | Director · Mar 19, 2025 – Nov 4, 2026 · Past |
| Jennifer Zibuda | Head of Investor Relations · Since at least Aug 19, 2026 |
| John J Boniface | Chief Scientific Officer · Since at least Jul 14, 2021 |
| John M Peltier | SVP of Lab Operations · Jul 14, 2021 – Jul 14, 2021 · Past |
| Joshua Phillips | Director · Since at least Jul 14, 2021 |
| Lee Anderson | Chief Commercial Officer · Since at least May 8, 2025 |
| Liana Burns | Head of Payer, Government & Strategic Partnerships · Since at least Nov 5, 2026 |
| Marcus Dean Wilson | Director · Since at least Jul 14, 2021 |
| Michael R Foley | Chief Medical Officer · Dec 30, 2021 – Jul 12, 2023 · Past |
| Nadia Altomare | Chief Commercial Officer · Jul 14, 2021 – Jun 9, 2023 · Past |
| Nichole L Martin | VP OF Q/R & HIPPA PRIV. OFF · Jul 14, 2021 – Jul 14, 2021 · Past |
| Nikki Martin | VP of Quality and Regulatory · Since at least Nov 5, 2026 |
| Paul Kearney | Chief Data Officer · Since at least Oct 1, 2021 |
| Ryan Trimble | Director · Since at least Jul 14, 2021 |
| Thomas Garite | VP, Clinical Sciences · Jul 14, 2021 – Aug 26, 2021 · Past |
| Tiffany Inglis | Chief Medical Officer & VP Medical Affairs · Since at least Oct 1, 2025 |
| Zhenya Lindgardt | President and CEO · Since at least Nov 8, 2021 |
Log in to ask 6ix AI your own questions about Sera Prognostics, Inc.